Jon Painter
Analyst · Sidoti & Company. Your line is now open
Thanks, Mike. Hello, everyone. It’s my pleasure to brief you on our second quarter results and our outlook for the second half of the year. Overall, we had an outstanding quarter with record adjusted EBITDA, the second-highest – and the second-highest adjusted earnings per share in our history. It was one of those quarters when everything went right, which led to a strong beat on both the top and bottom line. I’ll begin today’s business review with the financial highlights of the quarter. We finished the second quarter with revenue of $112 million, up 14% compared to the second quarter of 2015 and well above our guidance of $103 million to $105 million. Our acquisition of PAAL completed early this quarter had better-than-expected revenue performance as did other businesses in our Stock-Prep product line. Our Doctoring, Cleaning & Filtration and Wood Processing product lines also had stronger-than-expected revenue performance in Q2. Gross margins in the second quarter continued to be strong at 45%. Our adjusted EBITDA was a record $18 million or 16% of sales, up 14% compared to Q2 of last year. Our GAAP diluted earnings per share of $0.75 in the second quarter exceeded the top end of our guidance by $0.22 and included a $0.04 negative impact from currency translation. Our adjusted earnings per share was up 13% to $0.88. Excluding the impact of FX, our adjusted earnings per share increased 18% over Q2 of last year. The one area that was somewhat disappointing was our bookings, which were down $98 million, up only 5% compared to Q2 of 2015 despite the inclusion of bookings from PAAL. The weaker bookings reflect the general softening of markets in North America, Europe and China, and I’ll provide more detail on this in our outlook for the second half of the year later in my remarks. Finally, cash flow in the second quarter was quite strong at $14 million and we ended the quarter with net debt of $9 million. As you can see from Slide 6, FX continues to have a negative effect on our results when compared to Q2 of last year, albeit at a lower rate than previous quarters. Our internal growth for Q2, which excludes acquisitions and FX, was flat for revenue, down 8% for bookings and up 4% for adjusted earnings per share. Our internal growth for Q2 in parts and consumables revenue was up 1%, while bookings were down 2%. Excluding acquisitions and FX translation, our internal revenue growth for the first six months of the year was 4%. This compares with internal growth rates of 3.3% in 2015 and 6.4% in 2014. As many of you know, we have a goal to generate internal revenue growth over the long term of 4% to 6% on average, excluding the impact of acquisitions and FX. While we don’t expect to have internal growth every year, our long-term goal is that we will achieve an average growth rate of 4% to 6% annually depending, of course, on where we are in the economic cycle. This is an ambitious goal given the slower growth of our end markets, but we have several focused internal growth initiatives aimed at achieving this target. Looking at revenue and bookings trends on Slide 7. We saw generally weak industrial activity in the major regions of the world, which impacted our performance in Q2. Our second quarter revenue of $112 million was up 14% year-over-year due to the acquisition of PAAL, which is included in our Stock-Prep product line. Excluding the impact from FX and acquisitions, revenue was flat compared to Q2 of last year. Our bookings of $98 million were up 5%, which was also due to the contribution of PAAL. Excluding the impact of FX and acquisitions, our Q2 bookings were down 8% due largely to weakness in the other businesses included in our Stock-Prep product line. Turning now to our parts and consumables business. Our revenue for parts and consumables in the second quarter increased 6% and set a new record of $69 million in Q2. And this represented 62% of our total revenue. Our record revenue performance for Q2 was driven by the acquisition of PAAL as well as our fluid handling product line in Europe. Parts and consumables bookings were up 4% compared to a strong Q2 of last year to $65 million. This increase was largely due to the acquisition of PAAL as well as strong parts and consumables bookings from our wood processing product line. Next, I’d like to take a few minutes to provide an overview of our business activity and performance in each of the major geographic regions of the world. Let me begin with North America. The North American market is our largest and most impactful. The general slowdown in industrial economic activity and downstream demand in the U.S. is reflected in our rather lackluster performance in North America in Q2. We saw more – we also saw more market related downtime taken by U.S. paper mills, which negatively impacted our parts and consumables business. Our revenue in North America was down 9% to $54 million compared to the record-setting quarter of 2015. All of our major product lines saw modest declines compared to a strong Q2 of 2015. Bookings in North America were $46 million, down 10% compared to Q2 of last year and down 14% sequentially. The market conditions for spare parts and consumables in the U.S. paper industry has weakened, particularly for our Stock-Prep and Doctoring, Cleaning & Filtration product lines. That said, parts and consumables bookings at our wood processing product line increased 17% due to continued strength in the housing market. There were some notable price spots during the quarter. We booked three relatively large orders for our latest wool cleaning doctoring system from carbon fiber manufacturers in the U.S. While the combined value of these orders is just under $500,000, we also benefit from the future parts and consumables revenue stream that these installations create. This new product line and industry segment is an example of one of the internal growth initiatives I mentioned earlier in my remarks. This initiative is particularly impactful because it expands our presence into faster growing markets. I am also pleased to announce that during the second quarter, we’re again producing ceramic creping blades in the U.S. This new production line includes the state-of-the-art manufacturing and online inspection capabilities, which allows us to deliver world-class blades for North American customers locally with short lead times, something none of our competitors can do. As a refresher, creping is the most critical aspect of tissue making as it directly affects properties such as softness, strength and bulk. Our goal is to utilize our strong reputation in the tissue market to introduce these blades to our customers. We’re the world’s number one supplier of creping equipment for tissue machines. And with this new line, we are well-positioned to win a share of the $60 million annual market for these consumables. Increasing our market position for these consumables is another of the internal growth initiatives I mentioned earlier, and I’m happy to see the program achieve this milestone. As is the case in North America, Europe is also experiencing rather soft market conditions. It’s too early to tell what impact, if any, the Brexit vote will have on business levels in the U.K. as the potential negative impacts of Brexit are expected to be somewhat moderated by the positive impact of a weaker sterling. Incidentally, the U.K. typically represents 5% or under of our total revenue. Also, we’ve not seen much Brexit impact on our customer’s buying behavior in other parts of Europe. Our Q2 revenue in Europe was $33 million, up 86% and bookings of $31 million were up 46% compared to Q2 of last year. These positive results in Europe were largely due to our recent acquisition of PAAL. The integration of PAAL into the Kadant organization is going well and we’re diligently working on expanding PAAL’s presence into the North American market. After talking to potential customers in North America, we believe there is a real need for a reliable, high-performance, German-engineered baling equipment in this market. We’re also exploring various outsourcing opportunities with the goal of reducing the cost to some of PAAL’s components that are currently outsourced by bringing them in-house. Next, let’s take a look at Asia. Despite the government’s well-publicized efforts to stimulate the economy in China, we continue to see a relatively weak environment for capital projects so far in 2016 as overcapacity still seems to be weighing on the market. Our Q2 revenue in Asia was $14 million in both Q2 of this year and last year. Except for the revenue jump in the fourth quarter of 2015 when several large capital projects were shipped, quarterly revenues have been relatively stable over the past few years in this region. Our Q2 bookings in Asia were $12 million, down 14% from the second quarter of last year. While project activity was somewhat subdued in Q2, we did book several large orders from Chinese containerboard producers, including one for a large OCC system and two others for recycled fiber cleaning system upgrades with a combined value of more than $1 million. We also booked a large order for creping and fluid handling equipment for two new tissue machines being constructed in China, also with a combined value of nearly $1 million. In general, I would say Asia, and China in particular, is still working to its overcapacity issues and the weakness and uncertainty of the global economy is drawing this process out longer than what might normally have been the case if global trade and consumption were stronger. That said, I will say we are seeing an uptick in project activity in China, which gives us some optimism for 2017. Finally, I’d like to make a few comments about the Rest of the World. Our revenue in the Rest of the World saw a very nice uptick in Q2 to $11 million, up nearly 50% compared to the same period last year and included several large capital shipments of Strander and Stock-Prep equipment with a combined value of nearly $3 million. Our business in South America also had very strong performance in our Doctoring, Cleaning & Filtration product line, including a tissue project where Kadant was specified to the tissue machine supplier by the end user. Our strong reputation for high-performance creping equipment used in production of tissue provided us this preferred supplier status. Rest of the World bookings in the second quarter were up 23% compared to the same period last year to $8 million. While this region tends to be one of the more volatile regions in terms of capital projects, we’re well-positioned to take advantage of new project activity as it develops. Although market conditions in Brazil have been challenging, the integration of our acquisition a few years ago with our existing business in Brazil has gone extremely well and the combined business is performing at very good levels of profitability. Let me close my remarks with a few comments on our guidance for Q3 and the full year 2016. Fortunately, the first half of 2016 has turned out much stronger than we anticipated and PAAL has performed better than we projected. That said, we’re not increasing our guidance for the full year 2016 due to the weakening global market conditions that impacted our bookings in the second quarter and has moderated our outlook for the second half of the year. We’re narrowing our full year earnings per share guidance to $2.75 to $2.81 on revenues of $415 million to $421 million. Our adjusted earnings per share guidance, which exclude acquisitions related to cost and a gain, is $2.98 to $3.04. As I’ve mentioned in the past, FX is expected to have an impact on our expected growth rate for 2016 and 2015, reducing revenue and adjusted earnings per share by 3% and 4%, respectively. For the third quarter of 2016, we expect to achieve GAAP diluted earnings per share of $0.62 to $0.65 on revenues of $103 million to $105 million. I’ll now pass the call over to Mike for some additional details on our financial performance in the quarter. Mike?